{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.8","upperLimit":"23.9","value":"17.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"}],"units":"Participants"}],"description":"Time to transformation to AML is defined as the time from registration to the transformation of MDS to AML or death of any cause. Participants not meeting these criteria were censored at the date of last follow-up. This outcome was estimated using the Kaplan Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Adult patients with MDS receive treatment with vatalanib.\n\nvatalanib: Pts registered before 1/15/05 1250 mg/day PO After 1/15/05: Start w/ 750 mg/day PO; escalate q 4 wks in absence of Grade 2 or \\> tox (1st increase=1000mg/day; 2nd increase 1250 mg/day)","id":"OG000","title":"Vatalanib"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Duration of study (up to 5 years)","title":"Time to Transformation to AML","type":"PRIMARY","unitOfMeasure":"months"}